1. Scrip
  2. >>R&D
  3. >>Clinical Trials

IBD Market Snapshot: New Medicines Try To Address Patient, Physician Demands

Oral Drugs, Novel Biologics Offer New Options

 
• By Mandy Jackson

Remission rates with existing therapies leave much room for improvement, so a variety of treatments are needed – leaving major players attempting to carve unique paths in a crowded market.

Modern process Intestinal inner organs disease treatment design concept with Tiny People
Doctors and patients are seeing some treatment gains from new medicines • Source: Shutterstock

New drugs are looking to enter the mature inflammatory bowel disease market by focusing on the remaining unmet needs, with clinical development programs aimed at improving remission rates beyond what is possible with existing therapies and maintaining remission for longer periods of time, while providing relief in the near-term from symptoms that patients describe as debilitating aspects of ulcerative colitis and Crohn’s disease that impact their daily lives, such as bowel urgency.

Oral JAK inhibitors and S1P receptor modulators are just the start for novel mechanisms coming to inflammatory bowel disease (IBD), a market currently dominated by anti-TNF antibodies and other biologics after ulcerative colitis (UC) and Crohn’s disease (CD) patients progress on conventional therapies

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

More from R&D

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.